Press releases
Releases open in a new window/tab – close to return to the list below
5th January 2009 – Stem Cell Sciences signs further licence agreement for stem cell technology with major pharmaceutical company
29th December 2008 – Technique for creating authentic rat embryonic stem cells published in ‘Cell’
20th November 2008 – Stem Cell Sciences signs service agreement with Pfizer to provide access to proprietary technologies and methods
14th November 2008 – Stem Cell Sciences reinforces its international patent position in stem cell technologies
11th November 2008 – SCS stem licenses cell technology to leading provider of genetically modified models for pharmaceutical research
10th November 2008 – Stem Cell Sciences enters into services agreement with Huntington's Research Group, CHDI Foundation Inc.
24th October 2008 – Technique for rapidly reprogramming adult cells into stem cells published in PLoS Biology
8th October 2008 – Stem Cell Sciences in-licenses technology from University of Cambridge for reprogramming adult cells into stem cells
2nd September 2008 – Stem Cell Sciences announces the creation of the world’s first authentic rat embryonic stem cells from its exclusively licensed technology
9.7.2008 – Stem Cell Sciences granted UK patent for new growth medium to revolutionize growth of authentic embryonic stem cells
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the UK Patent Office has granted it a patent covering the Company’s new range of stem cell culture media. The new Culticell iSTEM™ range uses the inhibitor based technology discovered by Professor Austin Smith and recently published in Nature journal (vol. 453, pp.519-523).
18.6.2008 – Stem Cell Sciences licenses-in fluorescent protein technology to enhance stemcell research tools and services offerings
Stem Cell Sciences plc (AIM:STEM, ASX:STC), a leading provider of stem cells and associated technologies for drug discovery, today announced the licensing of certain rights to green fluorescent protein (GFP) technology from Prolume Ltd (Arizona, USA).
5.6.2008 – Stem Cell Sciences granted European patent on HEScGRO™ and EScGRO™ media
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the European Patent Office has granted a patent that protects its existing range of embryonic stem cell culture media. The media, marketed in Europe under the brands HEScGRO™ and EScGRO™, are used in the culture of embryonic stem cells from human and mouse, respectively.
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the European Patent Office (“EPO”) has granted it a second patent for ‘Nanog’, a key factor used to convert adult cells back into a pluripotent state. With this technology, adult cells can be reprogrammed to behave like embryonic stem cells, thus avoiding the controversy associated with using embryos.
22.5.2008 – Stem Cell Sciences launches novel stem media based on new understanding of ES cell self-renewal published in Nature by Prof Austin Smith
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced the launch of Culticell iSTEM, a novel, serum-free, feeder-free embryonic stem (ES) cell research media product, that maintains cells in their basal, pluripotent state. Culticell iSTEM provides researchers with a purer starting point for investigating the biological potential of ES cells.
14.5.2008 – Stem Cell Sciences granted broad US stem cell media patent
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the US Patent and Trademark Office (“USPTO”) has granted its patent for technology that improves the efficiency of the culture and derivation of embryonic stem cells which leads to an increased purity of the cells.
30.1.2008 – Stem Cell Sciences Enters Agreement with Myelin Repair Foundation
STEM CELL SCIENCES ENTERS AGREEMENT WITH MYELIN REPAIR FOUNDATION TO DEVELOP SUSTAINABLE CELL SOURCES FOR CNS DRUG DISCOVERY (“Stem Cell Sciences”, “SCS”) 30th January 2008 Stem Cell Sciences plc (AIM:STEM, ASX:STC) has entered an agreement with the Myelin Repair Foundation (MRF, Saratoga, CA) for the development of techniques that will lead to scalable and sustainable sources of uniform human brain cells for research, target validation and drug discovery assays.
24.12.2007 – SCS signs Diabetes Agreement
STEM CELL SCIENCES ENTERS INTO DIABETES R&D AGREEMENT WITH MAJOR PHARMACEUTICAL COMPANY ("Stem Cell Sciences", "SCS") 24 December 2007 Cambridge, U.K. – Stem Cell Sciences plc (AIM: STEM, ASX: STC) the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research, today announced the signing of a contract research agreement with a major biopharmaceutical company. Under the terms of the agreement Stem Cell Sciences will validate its suite of cell processing technologies for the scaled, automated production of human embryonic stem c
19.11.2007 – STEM CELL SCIENCES APPOINTS ALASTAIR RIDDELL AS CEO
Stem Cell Sciences plc (SCS, AIM:STEM, ASX: STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces today the appointment of Dr Alastair James Riddell, aged 58, as Chief Executive Officer (CEO).
23.10.2007 – Stem Cell Sciences to develop novel muscle stem cells for drug discovery and toxicology
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, today announced the signing of an exclusive agreement with San Raffaele Scientific Institute (Milan, Italy) covering assay validation and future commercialisation of novel human muscle stem cells for drug discovery and toxicology applications. Financial terms were not disclosed.
Stem Cell Sciences is pleased to announce the exclusive in-licensing of a breakthrough technology. This is expected to significantly accelerate the application of human embryonic stem (ES) cells in both research and cell-based therapies.
Stem Cell Sciences plc, (LSE: AIM, 'STEM') has licensed the use of their novel mouse neural stem cell technology to Merck & Co., Inc. for research use. Financial terms were not disclosed, but include a signing fee and milestone payments.
Stem Cell Sciences plc (AIM: STEM), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and novel cell-based therapies, is pleased to announce that it has signed a Material Transfer Agreement (“MTA”) and Option to License with AIM-listed Henderson Morley plc (AIM: HML). This agreement allows Stem Cell Sciences (SCS) to explore the use of Henderson Morley’s (HM) novel L-particles and PREPS technology (“Technology”) in the design of unique stem cell based assays.
25.1.2007 – AIM - Millipore’s HEScGRO™ Medium Advances Human Embryonic Stem Cell Research
As a direct result of an agreement between Millipore and Stem Cell Sciences, announced in October 2006, Millipore Corporation have today announced the availability of HEScGRO animal component-free medium for human embryonic stem cell research.